Journal of Clinical Oncology
Articles in this Issue
Disparities in inpatient treatment delivery for gynecologic cancers: A national analysis using machine learning.
e13694 Background: Patients with gynecologic malignancies are frequently hospitalized for cancer-related and unrelated ind...
Long-term oncologic outcomes of PSMA PET–guided salvage radiotherapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis.
5121 Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has demonstrated sup...
Operationalizing yoga as a quantifiable component of guideline-aligned multimodal exercise oncology care using RE-AIM.
e13589 Background: Exercise oncology guidelines (ACSM/ACS) recommend ≥150 minutes/week of moderate-intensity aerobic activ...
Drivers of early readmission and mortality after metastatic spinal cord compression in cervical cancer: Real-world evidence on disease progression, infection, and palliative gaps.
e17523 Background: Metastatic spinal cord compression (MSCC) is a catastrophic complication of cervical cancer, yet real-w...
Clinical significance of <i>EGFR</i> amplification in patients with <i>EGFR</i> -mutated metastatic non–small cell lung cancer receiving first-line osimertinib.
8643 Background: With rapidly expanding first-line options for patients (pts) with EGFR...
"Who even talks to her anymore?" Misalignment between cervical cancer care landscape and community awareness in Rwanda.
1601 Background: Cervical cancer remains the most common female cancer in Rwanda. Despite the significant advancement in e...
Genomic determinants of metastatic burden and survival in metastatic urothelial carcinoma.
4572 Background: Metastatic urothelial carcinoma (mUC) has variable outcomes. Metastatic site count (MSC) correlates with...
Evaluation of adnexal features and histological response to intralesional SP-002 in nodular basal cell carcinoma.
2596 Background: No FDA approved nonsurgical therapies exist for primary nBCC at high-risk sites, e.g., H-zone, representi...
Menopausal hormone therapy use and counseling patterns among surgically menopausal BRCA mutation carriers.
e12736 Background: Risk-reducing salpingo-oophorectomy (RRSO) for BRCA mutation carriers (BRCAm) is recommended by age 35–...
Real-world conversion surgery, survival outcomes, and safety of atezolizumab plus bevacizumab with TACE in unresectable hepatocellular carcinoma.
e16223 Background: Hepatocellular carcinoma (HCC) remains challenging to manage once unresectable. Although atezolizumab p...
Modified monobenzone supercarriers as targeted therapies for metastatic melanoma.
e21530 Background: Melanoma is the deadliest form of skin cancer, with a five-year survival rate of ~35% once metastasis o...
Linperlisib plus CHOP for newly diagnosed peripheral T-cell lymphoma: A single-arm, phase Ib/II study (LINCH trial).
7004 Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous type of aggressive non-Hodgkin lymphoma with poor pr...
Early-onset colorectal cancer hospitalizations in the United States: Metastatic burden, comorbidity, and mortality.
e15567 Background: The incidence of early-onset colorectal cancer (CRC) is increasing in the United States; however, natio...
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
TPS1162 Background: Triple-negative breast cancer (TNBC) refers to a heterogenous group of breast cancers that lack expres...
Impact of real-time artificial intelligence ultrasound system based on breast density in C4 breast lesions.
e12549 Background: Artificial intelligence–based computer-aided diagnosis (AI-CAD) systems are increasingly used in breast...
Impact of insurance status on disease severity and care utilization in hospitalized melanoma patients.
e21609 Background: Insurance status is a key determinant of access to cancer screening, timely diagnosis, and advanced onc...
Transforming oncology documentation exchange through intelligent automation: Operational outcomes and organizational lessons from a cancer center implementation.
e13659 Background: Timely exchange of oncology clinical documentation is vital for care coordination, yet many cancer cent...
Impact of mTOR pathway mutations on response to mTOR inhibition in neuroendocrine neoplasms (NENs).
e16328 Background: NENs are a rare and diverse group of tumors with no consensus on the ideal sequencing of therapies in a...
Evaluation of therapeutic response to neoadjuvant chemotherapy in breast carcinoma in a low-middle-income country.
e12642 Background: Neoadjuvant chemotherapy (NCT) is an established component of breast cancer management, offering tumor...
Nonoperative management of locally advanced resectable cutaneous squamous cell cancer of the head and neck with PD-1 blockade.
6111 Background: Head and neck cutaneous squamous cell carcinoma (cSCC) is common, increasing in incidence, and highly imm...
Risk factors for drug-induced pneumonitis from trastuzumab deruxtecan in patients with advanced HER2-positive solid malignancies.
e24153 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate that has demonstrated signifi...
Leveraging a hybrid tumor-informed and tumor-agnostic ctDNA assay for optimal ctDNA-MRD detection: A real-world study in Southeast Asia.
3058 Background: While tumor-informed ctDNA assays are the gold standard for minimal residual disease (MRD) detection, the...
Genomic markers of resistance to first-line (1L) therapy with a CDK4/6 inhibitor (CDKi) and endocrine therapy (ET) in patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (MBC).
1083 Background: Pts with HR+ MBC exhibit variable responses to 1L ET + CDKi therapy. We analyzed clinicopathologic featur...
Improving automated prostate cancer risk assessment: An ensemble LLM framework for clinical T-stage inference and NCCN risk stratification.
e17005 Background: We previously developed a hybrid framework combining LLMs and rule-based algorithms (RBA) for automated...
Trends in immunotherapy use and survival outcomes by metastatic pattern in metastatic triple-negative breast cancer.
1127 Background: KEYNOTE-355 demonstrated that adding pembrolizumab to chemotherapy improved progression-free and overall...